ReviewFrontiers in oncology2026
Research progress of antibody-drug conjugates in the treatment of endometrial cancer.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As a significant threat to women's health worldwide, the incidence of endometrial cancer is rising annually, and current treatment options have limited effectiveness for advanced-stage patients. The use of antibody-drug conjugates (ADCs) in the treatment of endometrial cancer shows great potential. ADCs achieve selective killing of tumor cells through the combination of monoclonal antibodies, linkers, and cytotoxic drugs, while reducing damage to normal tissues. ADCs targeting Trop-2, HER2, and FRα have demonstrated notable efficacy in clinical trials, such as Sacituzumab Govitecan (SG) and Trastuzumab Deruxtecan (T-DXd), which have shown high objective response rates in Trop-2 and HER2-positive patients, respectively. Furthermore, the combination of ADCs with other treatment modalities (such as chemotherapy and immunotherapy) further enhances efficacy. However, ADCs still face challenges regarding resistance and safety, and future efforts must focus on optimizing designs and exploring more emerging targets to achieve the goals of precision medicine. This article provides a focused narrative overview of recent advances in ADCs for the treatment of endometrial cancer, with a primary focus on key targets including Trop-2, HER2, FRα, and Nectin-4.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.